Articles by Adeline Siew, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Adeline Siew, PhD

First Biologic Approved in the EU for Gouty Arthritis

Mar 6, 2013

Ilaris (canakinumab), a selective, fully human, monoclonal antibody that inhibits interleukin-1 beta (IL-1 beta), has been approved in the EU for symptomatic pain relief in patients suffering from gouty arthritis whose condition cannot be managed with current treatments.

Roche and BioLamina Collaborate on Novel Cell Culture Systems

Mar 6, 2013

Roche and BioLamina have entered into a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will assess laminin-based in-vitro cell culture matrices that can offer physiological microenvironments for living cells.

AstraZeneca's Crestor Patents Ruled Invalid in Australia

Mar 6, 2013

AstraZeneca's three patents protecting Crestor (rosuvastatin) have been ruled invalid by the Federal Court of Australia.

Nanoparticles:Facilitating Targeted Drug Delivery in Cancer Therapy

Engineering nanoparticles with optimal properties for use in cancer therapies.
Mar 2, 2013

Engineering nanoparticles with optimal properties for use in cancer therapies.

Tackling Common Problems in Tableting and Tooling

The tableting science anti-research (TSAR) project seeks to understand why certain formulations stick to tablet tooling.
Mar 1, 2013

The tableting science anti-research (TSAR) project seeks to understand why certain formulations stick to tablet tooling.

Advancing Polymers for Solubility Enhancement

Pharmaceutical Technology brought together a panel of industry experts for a special forum to discuss solubilizing polymers and the related formulation strategies for poorly soluble drugs.
Mar 1, 2013

Pharmaceutical Technology brought together a panel of industry experts for a special forum to discuss solubilizing polymers and the related formulation strategies for poorly soluble drugs.

Ablynx and Spirogen Collaborate on Novel Toxin-Nanobody Drug Conjugates

Feb 27, 2013

Belgium drug developer Ablynx and UK-based Spirogen have entered into a research collaboration to discover and develop novel anticancer drug conjugates combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBDs), and the company's associated linker technology, with nanobodies generated using Ablynx's proprietary technology platform.

Sanofi's Six-In-One Pediatric Vaccine Recommended for European Approval

Feb 26, 2013

The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's six-in-one pediatric vaccine for marketing authorization.

Merck's Cilengitide Fails to Meet Primary Endpoint in Phase III Trial

Feb 25, 2013

Merck's investigational integrin inhibitor cilengitide did not meet its primary endpoint in the CENTRIC Phase III trial evaluating if the agent could prolong overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy).

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here